4-甲氧基噻吩-3-甲酰胺 | 65369-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-甲氧基噻吩-3-甲酰胺
• 英文名称: 4-methoxy-thiophene-3-carboxylic acid amide
• 英文别名: 3-methoxythiophene-4-carboxylic acid amide；4-Methoxythiophene-3-carboxamide
• CAS: 65369-29-1
• 化学式: C₆H₇NO₂S
• mdl: MFCD00067903
• 分子量: 157.193
• InChiKey: NYYTVZAHSFIFFN-UHFFFAOYSA-N

物化性质

• 熔点：
  120 °C
• 溶解度：
  19.4 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  4-甲氧基噻吩-3-羧酸甲酯 以89%的产率得到
  参考文献：
  名称：

  PRESS J. B.; HOFMANN C. M.; SAFIR S. R., J. ORG. CHEM., 1979, 44, NO 19, 3292-3296

  摘要：

  DOI：

文献信息

• Thiophene compounds and their manufacture
  申请人：BASF Aktiengesellschaft

  公开号：US04239897A1

  公开（公告）日：1980-12-16

  New thiophene compounds and a new process for the manufacture of thiophene compounds by dehydrogenating dihydrothiophene with certain halogen compounds. The products are starting materials for the manufacture of pharmaceuticals, dyes and plant protection agents and, in particular, for the manufacture of additives to foodstuffs, feeds, beverages and pharmaceuticals.

  新的噻吩化合物以及一种通过使用特定卤素化合物对二氢噻吩进行脱氢来制造噻吩化合物的新工艺。这些产品是制造药品、染料和植物保护剂的起始材料，特别是用于制造食品、饲料、饮料和药品的添加剂。
• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS
  申请人：Javaid Muhammad Hashim

  公开号：US20090281086A1

  公开（公告）日：2009-11-12

  A compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein: HetA is a C 5 arylene group, wherein the two substituent groups are on adjacent ring atoms, and where the group is further optionally substituted by one halo, amino or C 1-7 alkoxy group; Y is —CR C1 R C2 —(CH 2 ) m —, where m is 0 or 1, R C1 is selected from H, CH 3 and CF 3 , and R C2 is selected from H and CH 3 , or R C1 and R C2 together with the carbon atom to which they are attached form the 1,1-cyclopropylene group formula (A): R N1 and R N2 are independently selected from H and R, where R is optionally substituted C 1-10 alkyl, C 3-20 heterocyclyl and C 5-20 aryl; or R N1 and R N2 , together with the nitrogen atom to which they are attached form an optionally substituted 5-7 membered, nitrogen containing, heterocylic ring; HetB is selected from: (i), where Y 1 and Y 3 are independently selected from CH and N, Y 2 is selected from CX and N and X is H, Cl or F; and (ii), (aa), (bb) Q is O or S.

  化合物的公式（I）及其药学上可接受的盐，其中：HetA是C5芳基烷基，其中两个取代基位于相邻的环原子上，并且该基团还可以被一个卤素，氨基或C1-7烷氧基取代；Y是—CRC1RC2—（CH2）m—，其中m为0或1，RC1选自H，CH3和CF3，RC2选自H和CH3，或者RC1和RC2与它们附着的碳原子一起形成1,1-环丙基基团公式（A）：RN1和RN2独立地选自H和R，其中R是可选的取代C1-10烷基，C3-20杂环基和C5-20芳基；或者RN1和RN2，与它们附着的氮原子一起形成一个可选取代的5-7成员的含氮杂环；HetB选自：（i），其中Y1和Y3独立地选自CH和N，Y2选自CX和N，X为H，Cl或F；和（ii），（aa），（bb）Q为O或S。